Daniel Geynisman, MD
Medical Oncology · Philadelphia, PANPI 1437343597
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $63,316 of the $100,694 with a category attached, or 62.9%. 27 manufacturers reported payments, led by Exelixis Inc. at 43.5% of the total. Among medical oncology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 144 payments — averaging $699.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$44K
- Merck$15K
- Johnson & Johnson$7K
- E.r. Squibb & Sons, L.L.C.$5K
- Sanofi$4K
- Seagen Inc.$4K
- plus $22K from 21 others
Across 423 payments — averaging $9510.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.2M
- Merck$1M
- Regeneron$539K
- Seagen Inc.$470K
- Novartis$237K
- F. Hoffmann-la Roche AG$201K
- plus $348K from 7 others
What the payments were for
- Consulting fees$63,31663%
- Speaking & faculty fees$27,30227%
- Travel & lodging$6,7137%
- Food & beverage$3,3343%
- Education$290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 51 | $43,846 |
| Merck | 15 | $15,496 |
| Johnson & Johnson | 9 | $6,861 |
| E.r. Squibb & Sons, L.L.C. | 3 | $4,725 |
| Sanofi | 4 | $4,196 |
| Seagen Inc. | 3 | $3,603 |
| Avyxa Pharma, LLC | 5 | $3,426 |
| Eisai Inc. | 5 | $3,279 |
| AstraZeneca | 8 | $2,512 |
| Astellas Pharma Global Development | 2 | $2,387 |
| Bayer | 2 | $2,124 |
| Astellas Pharma US Inc | 2 | $2,000 |
| Dendreon Pharmaceuticals LLC | 1 | $1,750 |
| Pfizer | 9 | $1,648 |
| HRA Pharma RARE Diseases | 1 | $1,500 |
| Janssen Scientific Affairs, LLC | 1 | $818 |
| Daiichi Sankyo Inc. | 8 | $190 |
| Taiho Oncology, Inc. | 3 | $75 |
| Gilead | 2 | $52 |
| Novartis | 2 | $38 |
| GSK | 2 | $32 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $30 |
| Tolmar Pharmaceuticals, Inc. | 1 | $28 |
| Myovant Sciences Inc. | 1 | $23 |
| Genentech, Inc. | 1 | $20 |
| Bristol Myers Squibb | 1 | $20 |
| Foundation Medicine, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$100,694 in reported general payments places this provider in the 90th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 184 | $2,444,914 |
| NubeqaDarolutamide | 107 | $1,351,046 |
| CabometyxCabozantinib S-Malate | 41 | $1,050,169 |
| InlytaAxitinib | 53 | $852,502 |
| Abiraterone Acetate | 347 | $557,283 |
| ErleadaApalutamide | 39 | $448,662 |
| OrgovyxRelugolix | 143 | $375,322 |
| LenvimaLenvatinib Mesylate | 14 | $338,295 |
| MyrbetriqMirabegron | 20 | $12,306 |
| EliquisApixaban | 11 | $7,604 |
| Prednisone | 335 | $1,433 |
| Tamsulosin Hcl | 31 | $499 |
| Oxycodone Hcl | 32 | $339 |
| Bicalutamide | 21 | $324 |
| Ropinirole Hcl | 19 | $323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $2,000 | $2,457,220204 claims |
| BayerNubeqa | $2,124 | $1,351,046107 claims |
| Exelixis Inc.Cabometyx | $43,846 | $1,050,16941 claims |
| PfizerInlyta, Eliquis | $1,648 | $860,10664 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $818 | $557,283347 claims |
| Johnson & JohnsonErleada | $6,861 | $448,66239 claims |
| Eisai Inc.Lenvima | $3,279 | $338,29514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 238 medical oncology providers in Pennsylvania.
Other medical oncology in Philadelphia
- Carl JunePhiladelphia$9M
- Shayma KazmiPhiladelphia$619K
- Marcia BrosePhiladelphia$260K
- Adam CohenPhiladelphia$239K
- Daniel HallerPhiladelphia$227K
- Edith MitchellPhiladelphia$220K
- Elizabeth PlimackPhiladelphia$190K
- Alexander PerlPhiladelphia$176K
- Martin EdelmanPhiladelphia$157K
- Jean-Pierre IssaPhiladelphia$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.